iiinova — where your digital self keeps evolving

Adam Raymakers @araymakers.bsky.social · 11/09/2026

Just out! Our new paper in @jamadermatology.com investigating the budget impact of Vyjuvek and Zevaskyn in recessive dystrophic epidermolysis bullosa.

000

Adam Raymakers @araymakers.bsky.social · 01/06/2026

Excited to share this new work co-authored with Leah Rand & Mike Paulden in Health Affairs Forefront! There's been lots of talk about the relationship between innovation, cost-effectiveness analysis, and incremental cost-effectiveness thresholds. (1/4) www.healthaffairs.org/content/fore...

healthaffairs.org

Cost-Effectiveness Thresholds: Overvaluing Innovation, Undervaluing Health | Health Affairs Forefront

To address the gap between opportunity costs and cost-effectiveness thresholds, we must identify the marginal cost of a unit of health for health care systems.

110

Adam Raymakers @araymakers.bsky.social · 19/05/2026

Interested in how climate impact could be incorporated into health technology assessment? We leverage real-world evidence for triple therapy inhalers, estimates of the carbon footprint on inhalers, and bring it together in an HTA framework! #ISPORAnnual

000

Adam Raymakers @araymakers.bsky.social · 01/05/2026

Happy to share that I've joined the Editorial Board of the Journal of Cancer Policy as a Section Editor. Really excited to be part of the journal, work with the editorial board, and engage with authors submitting their research! sciencedirect.com/journal/jour...

010

Adam Raymakers @araymakers.bsky.social · 23/04/2026

It's been a few years but really excited to be back at Canada's Drug Agency Symposium 2026! Off to a great start with a plenary on international approaches to HTA with Suzanne McGurn, Sarah Emond, Natalie M., and Yannis Natsis. #CDAAMC26

000

Adam Raymakers @araymakers.bsky.social · 03/03/2026

Two abstracts accepted for ISPOR 2026 in Philadelphia! The 1st abstract illustrates a way to include climate impact into health technology assessment. The 2nd is an analysis of spending on new gene therapies for recessive dystrophic epidermolysis bullosa. See you in Philly!

000

Reposted by Adam Raymakers

USC Schaeffer @schaeffer.usc.edu · 18/02/2026

The FDA is increasingly turning to ad hoc expert panels instead of federal advisory committees for external advice. FDA watchers generally agree these expert panels "are likely unlawful," USC Schaeffer's @profgenkanter.bsky.social tells Regulatory Focus.

raps.org

Experts argue recent FDA expert panels may violate FACA requirements

The US Food and Drug Administration@s (FDA) increasing reliance on holding expert panels, rather than advisory committees, for external expert advice may violate the Federal Advisory Committee Act (FA...

023

Reposted by Adam Raymakers

Davene R. Wright, PhD @wrightcensored.bsky.social · 06/02/2026

We would like to recruit a stellar junior faculty member in the Division of Child Health Research and Policy @deptpopmed.bsky.social at Harvard. Please circulate this announcement widely! www.populationmedicine.org/divisions-ce...

populationmedicine.org

Faculty Positions | HPHCI: Department of Population Medicine

057

Adam Raymakers @araymakers.bsky.social · 09/10/2025

Some more @cnn.com coverage of our study, led by @wbfeldman.bsky.social, on greenhouse gas emissions associated with inhaler use in the US.

010

Adam Raymakers @araymakers.bsky.social · 06/10/2025

Really excited to share, and happy have been a part of, this new paper led by @wbfeldman.bsky.social out today in @jama.com! We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US. Read it here: jamanetwork.com/journals/jam...

172

Adam Raymakers @araymakers.bsky.social · 02/10/2025

New edition of the PORTAL Post (the @portalresearch.org monthly newsletter), featuring lots of great research, including our recent publication about modelling the budget impact of gene therapies to treat sickle cell disease in the US. Check it out here: www.linkedin.com/pulse/octobe...

linkedin.com

October 2025 | The future of the FDA, pediatric clinical trials, and the budget impact of sickle cell therapies.

On September 30, PORTAL hosted a symposium on the future of drug regulation at the FDA, featuring conversations with Peter Marks, former Director of the Center for Biologics Evaluation and Research (C...

010

Adam Raymakers @araymakers.bsky.social · 23/09/2025

Excited to share new research led by Jessica Harvey exploring the budget impact of gene therapies for sickle cell disease, with a focus on Medicaid programs. Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua. 🔗: link.springer.com/article/10.1...

link.springer.com

Modeling the Budgetary Impacts of Sickle Cell Disease Gene Therapies on State Medicaid Programs - Journal of General Internal Medicine

Journal of General Internal Medicine -

262

Adam Raymakers @araymakers.bsky.social · 19/08/2025

The Common Sense Oncology Fellowship program is now accepting applications. Definitely a great opportunity for anyone interested in health services research and oncology! commonsenseoncology.org/wp-content/u...

commonsenseoncology.org

000

Adam Raymakers @araymakers.bsky.social · 18/07/2025

'The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company’s hopes for the product following two patients’ deaths.' via @endpts.com endpoints.news/fda-asks-sar...

endpoints.news

Breaking: FDA will ask Sarepta to stop selling Duchenne treatment, following patient deaths

FDA to request Sarepta halt shipments of DMD drug Elevidys after two patient deaths, HHS official says. Trading of $SRPT shares paused after decline.

010

Adam Raymakers @araymakers.bsky.social · 17/07/2025

'Drugmakers [said] they were stockpiling drugs in the US as a strategy to curb the impact of potential pharma tariffs. In March, Ireland saw a massive 243% increase in pharma exports, compared to the same month last year.' via @annajbrown.bsky.social / @endpts.com endpoints.news/pharmaceutic...

endpoints.news

Pharma exports from Ireland climb again as Trump's drug tariffs inch closer

New data from Ireland’s Central Statistics Office suggest that pharmaceutical companies are exporting more inventory to the US as the threat of drug tariffs persists.

010

Reposted by Adam Raymakers

Madhu Pai, MD, PhD @madhupai.bsky.social · 16/07/2025

Fantastic postdoc fellowship opportunity @mcgill.ca! mcgill.wd3.myworkdayjobs.com/McGill_Caree...

02723

Adam Raymakers @araymakers.bsky.social · 09/07/2025

Always a super interesting read! Notably, amongst the top 20 CEOs, average compensation was greater than $30 million. Total compensation for the top 20 CEOs was more than $600,000,000. Also notable that there is only one woman amongst the top 20. via @andrewedunn.bsky.social / @endpts.com

endpoints.news

Biopharma's 20 highest-paid CEOs of 2024 with $20M+ paydays

Biopharma CEO median pay hit $4.73M in 2024, up 40%. 20 CEOs made over $20M, including Pfizer's Bourla, Vertex's Kewalramani, Amgen's Bradway & Royalty Pharma's Legorreta.

000

Adam Raymakers @araymakers.bsky.social · 03/07/2025

Just out! The new guidelines from the Canadian Patented Medicine Prices Review Board (PMPRB) have finally been released. Changes to take effect as of January 2026. #hta #drugprices www.canada.ca/en/patented-...

canada.ca

PMPRB releases new Guidelines to monitor and review drug prices - Canada.ca

PMPRB releases new Guidelines to monitor and review drug prices

011

Adam Raymakers @araymakers.bsky.social · 27/06/2025

A little work to make one of the local #Squamish trails a bit more friendly to those riding adaptive mountain bikes.

051

Reposted by Adam Raymakers

Aaron Kesselheim @akesselheim.bsky.social · 26/06/2025

New in @jama.com, Joseph Daval and I discuss legal issues surrounding ACIP including its role in setting government policy and dealing with politically-motivated agendas arising from its new membership: jamanetwork.com/journals/jam...

jamanetwork.com

Legal Challenges for the Advisory Committee on Immunization Practices

This Perspective offers an analysis of the legal foundations in the context of these and other challenges to the role of the Advisory Committee on Immunization Practices.

053

Adam Raymakers @araymakers.bsky.social · 25/06/2025

The clinical aspect & decision aside, it's problematic for health systems that BioMarin priced Brineura at $1 million. If companies didn't charge these prices, decisions would be easier & less restrictive. Note: Brineura's net sales in 2024 were $170 million (US alone). www.cbc.ca/news/canada/...

cbc.ca

Vancouver Island family heartbroken as B.C. stops funding $1M drug for girl with terminal condition | CBC News

Charleigh Pollock's mother says the family has gone through a roller-coaster of emotions since learning the B.C. government has pulled funding for the drug their daughter needs for the rare and termin...

030

Adam Raymakers @araymakers.bsky.social · 24/06/2025

'A 2023 analysis of more than 20 million deaths across the world found that hot days and days with bad air quality both resulted in higher-than-normal mortality rates. But periods in which heat and pollution are combined were even more deadly.' via @nytimes.com

000

Adam Raymakers @araymakers.bsky.social · 23/06/2025

Looking for a recent paper that reports on HRQoL via EQ-5D-5L/3L scores, that specifically reports on the each of the domains/levels of the EQ-5D. Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social #healtheconomics #hspr #QALYs

001

Reposted by Adam Raymakers

Holly Fernandez Lynch @hollylynchez.bsky.social · 17/06/2025

Our special issue, “Advancing Trust in Science: Institutional Obligations to Promote Research Integrity,” is now live in @jlme-journal.bsky.social. Check out the full line up of leading voices on spotting, addressing, and preventing misconduct. www.cambridge.org/core/journal...

01812

Adam Raymakers @araymakers.bsky.social · 17/06/2025

I've attended this event in the past and it's absolutely fantastic! Not to mention Galway is an incredibly fun city to visit. Highly recommend!

041

Adam Raymakers @araymakers.bsky.social · 17/06/2025

Added a few more folks recently so thought I'd re-share. If I've missed you, reach out and I'll add you to the list! #healtheconomics

052

Adam Raymakers @araymakers.bsky.social · 16/06/2025

Super interesting story about Novo Nordisk and their Canadian patents. '... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!' by @dereklowe.bsky.social www.science.org/content/blog...

science.org

Novo Nordisk's Canadian Mistake

010

Adam Raymakers @araymakers.bsky.social · 10/06/2025

Great and engaging panel discussion about the future of the Inflation Reduction Act by @benro.me and Chris Cai (both from @portalresearch.org), @dusetzinas.bsky.social (Vanderbilt Health Policy), and Alyson Bancroft (@p4ad.bsky.social)! #ARM25

052

Adam Raymakers @araymakers.bsky.social · 09/06/2025

Presenting some work on spending associated with drugs for ultra-rare diseases at the @academyhealth.bsky.social Annual Research Meeting! #arm25 @portalresearch.org

021

Adam Raymakers @araymakers.bsky.social · 08/06/2025

Chris Cai from @portalresearch.org presenting on private equity acquisitions of health care delivery organizations at the @academyhealth.bsky.social Annual Research Meeting. #arm25

130

Reposted by Adam Raymakers

Theresa Kim, PhD, MS @tyk314.net · 08/06/2025

Hey, #arm2025 attendees, @josh-caplan.bsky.social , @academyhealth.bsky.social , and @aaronecarroll.bsky.social , I made the #hspr strarter pack last year. Here are great people and orgs to follow. Enjoy Twin Cities. Still affected by fed travel limits. #hspr

185

Adam Raymakers @araymakers.bsky.social · 07/06/2025

On my way to the Academy Health (@academyhealth.bsky.social) Annual Research Meeting in Minneapolis with @jerryavorn.bsky.social in my ear! #arm2025 @portalresearch.org

012

Adam Raymakers @araymakers.bsky.social · 06/06/2025

Looking forward to attending my first ever Academy Health Annual Research Meeting with fellow @portalresearch.org members @benro.me and Chris Cai! I'll be presenting some work on spending associated with drugs for ultra-rare diseases on Sunday. See you there! #arm2025 @academyhealth.bsky.social

061

Adam Raymakers @araymakers.bsky.social · 06/06/2025

Great talk today by Dr Beate Sander at the annual Vancouver Health Economics Methodology Meeting on economic evidence as a component of public health decision making, with lots of discussion about the societal perspective! #healtheconomics #hta

010

Adam Raymakers @araymakers.bsky.social · 27/05/2025

Happy to have been able to help out with new research led by Ian Liu, with co-authors @asarpatwari.bsky.social and @akesselheim.bsky.social (@portalresearch.org). We looked at trials, labelling changes, and revenues associated with the Best Pharmaceuticals for Children Act.

110

Reposted by Adam Raymakers

Tahir Amin @tahiramin.bsky.social · 27/05/2025

An internal Celgene presentation from 2014. Celgene’s primary patent on Revlimd expired in 2019. Despite that, Celgene estimated it had a 65% chance of extending its Revlimid monopoly in the U.S. until 2026.

134

Reposted by Adam Raymakers

aaronecarroll.bsky.social @aaronecarroll.bsky.social · 16/05/2025

When research gets sidelined, it’s stalls progress, innovation, and disrupts patient care. @AcademyHealth.bsky.social is gathering stories from our field to make that case clear. If your work’s been disrupted, we want to hear from you: docs.google.com/forms/d/e/1F...

docs.google.com

Voices of HSR – Story Collection

AcademyHealth is collecting information and stories from the Health Services Research field to build community and solidarity, to advocate on the field’s behalf, and to educate others broadly about...

153

Reposted by Adam Raymakers

Stacie Dusetzina @dusetzinas.bsky.social · 16/05/2025

Excited to share new work in @jama.com on launch prices for cancer drugs in Medicare Part D. Prices are going up, but no trend change post-IRA. Mean monthly launch prices increased from $10,954 in 2012-2014 to $27,891 in 2023-2025. Many thanks to @arnoldventures.bsky.social for funding this work!

jamanetwork.com

Trends in Launch Prices and Price Increases for Self-Administered Anticancer Drugs in Medicare

This study examines trends in launch prices and price increases for anticancer therapies covered under Medicare Part D and approved from 2010 to 2024.

1298